Combined methotrexate (MTX) and fluorouracil (FU) has heen used for many years to treat neoplastic diseases. However, clinical and laboratory snldies are still carried out to explain the changes that the therapeutic and toxic effects undergo when MTX and FU are used as a combined therapy. The schedules of combined therapy used so far have either proved not very effective in retrospective assessment, or caused severe tOJ{jc symptoms. Antineoplastic drugs damage the matrix cells of bone mar· row; the effect of commonly used doses more frequently concerns immature forms of blood morphotic elements. Methotrexate belongs to the group of drugs with very potent toxic effect on mOlphotic elements of peripheral blood; the effect of fluorouracil is weaker. Methotrexate causes anemia due to the deficiency of folic acid. For correct metabolism of folic acid, cyanocobaJamin is necessary. With deficiency, or lack of cyanocobalamin, the process is disturbed and a marked decrease of folic acid concentration in erythrocytes occurs. The main circulating and accumulated folate is N 5 -methyltetrahydrofolate which is metabolically inactive itself. In the presented study the morphotic elements were determined iI1 mice inoculated i.p. with LIllO lymphoid leukemic cells. The determinations were carried out on the 14 rh day after LIllO inoculation. In untreated animals a decrease of hemoglobin, hematocrit and erythrocyte count values took place as compared with the values observed in healthy mice.
Introduction
Combined methotrexate and fluorouracil therapy which has been used for several years to treat § Author to whom correspondence should be addressed.
Pteridines/ Vol. 8 / No . 3 neoplastic diseases, gives heterogenous interactions in retrospective assessment. The evidence that the problem of interactions between methotrexate and fluorouracil has not been fully elucidated yet comes from studies, publications and conferences on this subject still organized by various oncological centres (1, 2 , 3, 4, 5 ) .
First experimental studies on animals using inoculated neoplasms were carried out in the 1960' s (6) . The technique of neoplasm passage used at that time yelded results whose interpretation was difficult. The basis for interaction was to be synergistic activity involving the blockade of dihydrofolate reductase by methotrexate, and of thymidilane synthase by fluorouracil.
More recent studies have demonstrated that fluorouracil and methotrexate, despite their ditlerent me chanisms of antineoplastic actiyity, can compete for the utilization of exo-and endogenous substances for their systemic turnover that, which is important, also takes place in the neoplastic cells (7, 8 ) . In this context, the order of administration of these drugs may affect the efficacy of treatment and their toxicity (9, 10, 11 ) .
The aims of the study was to assess the effect of methotrexate and fluorouracil treatment schedule o n hematologic parameters, serum and erythrocyte levels of N ' -methyltetrahydrofolate and se rum cyanoco balamin levels in mice with L 1210 ly mphoid leukemia .
Materials and Method

Therapeutics
Methotrexate (Methotrexate~ LederLe ) and fluo rouracil (Fluoroblastin, Farmitalia) were diluted in 0 .9 % sodium chloride just before the injection . Drugs were premixed at different concentrations so as to obtain for all the used doses injection volumes of 0 .01 mlll g b .w. Methotrexate and/ o r fluorouracil were administered i.p . as single d oses, according to the fo llowing sche dules: -F2M-fluorouracil administered 2h before methotrexate, -MFS-simultaneous administration of both drugs, -M2F-methotre xate administered 2h before fluo rouracil. -MTX -administered as m o notherapy -FU -administer-ed as monotherapy.
The drugs were administered at the following doses: MTX-20 mg/ kg or 40 mg/ kg, FU 20 mg/ kg or 40 mg/ kg. Various combinations of doses were used in the combined therapy.
L eukemia
Lymphoid leukemia L1210 cells were obteined from the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Wroclaw ), and were maintained by serial passage in the ascitic fluid of DBA/2 mice . Leukemic cells L12IO from the fluid were resuspended in 0,9% sodium chloride and 10 2 cells/ mouse were injected i.p . into BDF J recipients .
Animals
The experiments were performed on mice of DBA/2 strain and mice of BDFI strain-the first generation obtained by cross-breeding mice of DBA/2 and BALB/ c strains. The animals were purchased from the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Wroclaw). On arrival the animals were 8-10 weeks old and their body weight was 18 -22 g . They were kept in appropriate cages with standard laboratory chow and water ad libitum, under natural lighting conditions, humidity and temperature m eeting the standards set up for keeping this type of animals .
Methods
Assessment of effects of drugs on morphotic elements of peripheral blood in mice
The determination of morpho tic peripheraJ blood elements were performed in normal mice and in thos~ inoculat~d i.\1. with 1 Q2 L l2l Q leukemic cells. Blood for investigations was collected from the retroocular venous plexus on the 14th day after the administration of MTX, FU or the combination of both drugs according to the three schedules given in section 1 . Hematocrit was determined using microhematocrit method. Hemoglobin level was evaluated b y cyanmethemoglobin method. The number of erythrocytes was detennined by means of a Burker hemocytometer. Leukocytes were counted by means of a Burker chamber. Platelet count was obtained by an indirect method according to Fonio ( 12 ) Cyanocobalamin determination in mouse serum after combined methotrexate and fluorouracil therapy Cyanocobalamin was determined in mouse serum by radioimmunoassay using a Vitamin B12/ Folate Dual RIA Kit (Kodak-Diagnostic).
The employed method makes use of the competition between cyanocobalamin present in the investigated serum samples and s7Co-labelled cyanocobalamin for specific binding sites of Castle's inPteridines/ Vol. 8 / N o . 3 trinsic factor.
After adding the label to the investigated serum, cyanocobalamin is rele3.sed from binding proteins with a denaturing agent. Then the samples are incubated with Castle's intrinsic factor. The free cyanocobalamin fraction, not bound with the binding protein is absorbed with medicinal charcoal. After centrifugation of the samples the activity of cyanocobalamin bound with Castle's intrinsic factor is measured in the liquid over the precipitate (supernatant). The activity in nonmeasured samples is compared with that of the samples contammg known concentrations of cyanocobalamin . The measurements of active samples were performed using an automatic gamma counter. Cyanocobalamin levels were determined in serum samples &om healthy mice and those which had been inoculated i.p. with 10 2 L1210 leukemic cells. The blood for investigations was collected from cardiac chambers on the 14th day ( 13) after the administration of MTX or FU and combined MTX and FU administration according to the three described schedules at doses given in section therapeutics. Determination of cyanocobalamin !e\"els w as additionally performed in the serum of health\" mice and untreated ones inoculated \\'ith LIllO leukemia.
v ' -methyltetrahydroJolate determination in mouSe serum after combined methotrexate and fluorouracil therapy N 5 methyltetrahydrofo1ate ( 5-MTHF) was determined in mouse serum by radioimmunoassay using a VitaJ.nin B 12 /Folate Dual RIAL Kit (KvdakDiagnostic) .
The employed method makes use of the competition between folate present in the serum : 5-MTHF and labelled 125J N 5 -methyltetrahydrofolate for specific sites of betalactoglobulin, a folatebinding protein .
After adding the label to the investigated serum, 5-MTHF is released from binding proteins with a denaturing agent. Then the samples are incubated with folate-binding protei!1. The free 5-MTHF fraction, not bound with the binding protein, is absorbed with medicinal charcoal. After centrifugation of the samples, the activity of 5-MTHF bound with folate-binding protein is measured in the liqiud over the precipitate (supernatant).
The activity in non-measured samples is compared with that of the samples containing known concentrations of 5-MTHF. The activity in non-measured samples is COr!1-pared with that of the samples containing known concentrations of 5-MTHF. The activity of samples was measured with an automatic gamma counter.
5 -MTHF levels were determined in the blood taken from healthy mice and from mice which had been inoculated i.p. with 10 2 L1210 leukemic cells. The blood for investigations was collected from cardiac chambers on the 14th day after the administration of MTX, FU or combined MTX and FU therapy according to the three schedules described in section I, at doses given in section theraptutics. 5-MTHF levels were additionally determined in the blood of healthy mice which had not received any cinlg and of untreated mice inoculated with L1210 leukemia.
The blood was collected into test tubes containing 5% Na 1 EDTA solution. Hematocrit was determined in a hematocrit centrifuge.
After determination of whole blood 5 -MTHF level, the concentration in erythrocytes was obtained dividing the result by the hematocrit value. 
Statistical analysis
The eftects of the drugs on the selected morphological parameters of blood as '.vell as on cyanocobalamin and S-MTHF levels were evaluated by calculating the mean values, SD and SEM (14) .
The difierence of means was checked using Student-t test. The difference was regarded as statistically significant when the zero hypothesis could be rejected at sig."1ificance level p s O.OS ( 14, 15) . Table 1 presents the effects of combined MTXj FU therapy administered according to three schedules, on the parameters of peripheral blood morpho tic elements in healthy mice. The drugs were also administered as monotherapy .
Results
Hematological assessment of effects of MTX/FU combined therapy according to the schedule of treatment
MTX and FU were administered at two doses : 20 mg/ kg and 40 mg/ kg. On the 14th day after administration of MTX or FU at the 20 mg/kg dose, no statistically significant changes of the evaluated parameters of peripheral blood morphotic elements were found. Combined therapy using 20 mg/ kg doses according to the F2M (FU administered first ) or MFs (simultaneous administration of both drugs ) schedules also did not result in any changes of the evaluated parameters, whereas after combined therapy involving earlier administration of MTX (M2F), a significant decrease of hemoglobin, hematocrit and erythrocyte levels was observed . On the 14th day after the administratio n of 40 mg/ kg MTX doses, a decrease of hemoglobin and hematocrit values was observed. FU administered at the dose of 40 mg/kg did not result in any changes of the evaluated peripheral blood parameters, whereas after com.bined administration of MTX and FU at 40 m.g/kg doses a significant decrease of hemoglobin level was demonstrated in all animals, regardless of the schedule of tratment, as compared with the values obtained in control mice. The lowest value was obtained after combined treatment involving the administration of MTX prior to FU (M2F) . In this treatment schedule (M2F) a decrease of hematocrit, erythrocyte and platelet counts were observed as well. Table 2 presents the effects of combined MTX/ FU therapy administered according to three schedules on the parameters of peripheral blood Table 1 Number of animals in group n=5, x ± SEM-mean±standard error mean, Statistically significant differences for p:S:; morphotic elements in mice inoculated with L 1210 leukemia, The drugs were also administered as monotherapy. Identical doses and treatment schedules as in healthy mice were used. On the 14th day after inoculation with 10 2 L 1210 leukemic cells, anemia was observed in the experimental mice. There was a significant decrease of hemoglobin, hematocrit and erythrocyte values as compared with those obtained from healthy controls, Mter MTX and/or FU administration, the following changes were observed in peripheral blood parameters as compared with healthy, untreated mice: There was a significant increase of leukocyte count after MTX monotherapy at 20 mg/kg dose, as well as after combined MTX and FU therapy at 20 mg/kg doses according to the F2M (FU administered first) and MFs (simultaneous administration of both drugs) schedules. In comparison with untreated leukemic mice an increase of hemoglobin, hematocrit and erythrocyte values was obtained after administration of the drugs at 40 mg/kg doses according to the M2F schedule (MTX administered first), In the other groups of mice treated with such MTX doses in mono therapy or combined therapy according to MFs or F2M schedules, no increases of hemoglobin, hematocrit and erythrocyte values Pteridines/ VoL 8/ No. 3 were obtained in comparison with untreated mlce inoculated with L1210 leukemia.
Effect of methotrexate and fluorouracil Oil the mouse serum level of cyanocobalamin; according to the schedule of treatment
The effects of MTX and FU on serum cyanocobalamin levels were investigated using these drugs in monotherapy at 20 mg/kg and 40 mg/ kg doses. The effect of combined therapy was investigated administering combinations of these doses, Table 3 presents cyanocobalamin levels in the serum of healthy mice, on the 14th day after the administration of the drug(s). Table 4 presents statistical analysis of the obtained results.
After the administration of MTX alone at 20 mg/kg doses the level of cyanocobalamin was lower than that obtained in healthy control mice. FU administered as monotherapy did not affect cyanocobalamin level in mouse serum. In most animal groups after simultaneous MTX and FU administration cyanocobalamin levels were significantly lower than the control values.
After MTX administered prior to FU (M2F) cyanocobalamin levels were significantly lower in (40 ) MTX (20 ) FU (40) FU (20) MTX (40 Table 4 . Statistically significant differences of serum cyanocobalamine levels between the groups of healthy BDFl mice after adrninistration of MTX, FU and combined therapy with both drugs according to different schedules r Control group; cyanocobalamine level normal Table 5 . The same doses and treatment schedules as in healthy mice were used. Table 6 presents statistical analysis of the obtained results .
It has been demonstrated that cyanocobalamin level in the serum of mice with L1210 leukemia is significantly lower than that obtained in the group of healthy mice. After MTX and FU monotherapies, as well as after combined therapy involving administration of the drugs in different orders, cyanocobalamin levels still remained lower than control ones .
After combined therapy involving administration of MTX prior to FU the increasing tendency is observed with respect to cyanocobalamin level, or a statistically significant increase is obtained in comparison with the values resulting from combined therapy involving simultaneous administration of the drugs or administration of FU prior to MTX.
It was noted that only after administration of Number of animals in group n=10 . X ±SEM-mean ± standard error mean. Table 6 . Statistically significant differences of serum cyanocobalamine levels between the groups of EDF, mice with LI210 leukemia after administration of MTX, FU and combined therapy with both drugs according to different schedules
G ro up s\'mbols as in Table 5 . Significance level set at p::; 0 .05 .
.\lTX first in combined therapy with FU the obtained cyanocobalamin levels were higher in all L'-le groups of mice with L1210 leukemia than those observed in untreated leukemic mice. Additionally, after administrating the drugs at the doses of 20 mg/kg for MTX and 40 mg/ kg for FU , cyanocobalamin level was the same as in healthy mice (Table 6 ) .
Effect of methotrexate and fluorouracil on mouse blood serum level of 5-MTHF; according to the schedule of treatment
The effects of the drugs on 5-MTHF level in the serum of healthy mice were investigated for 20 mg/ kg and 40 mg/kg doses of MTX and FU in monotherapy. The effects of combined therapy with MTX and FU according to different schedules were investigated using combinations of these doses . Table 7 presents the levels of 5-MTHF in the serum of healthy mice obtained on the 14th day after administration of the drug(s). nificantly higher than in untreated healthy mice . After the lower dose of MTX, 20 mg/kg, 5-MTHF level did not differ from the value obtained for control mice . FU administration did not result in any changes of serum 5-MTHF levels . In most groups of healthy animals, after com- Table 8 . Statistically significant differences between the levels of N 5 -methyltetrahydrofolatein the serum of healthy EDF, mice after administration of MTX, FU and combined therapy according to different schedules Group sumbols as in Table 7 . Significance level set at p ::S; 0 .05 .
bined therapy involving earlier injection of MTX, 5-MTHF levels in serum were significantly higher than those obtained in the groups treated with F 2M (earlier injection of FU) o r MFS (simultaneous administration) treatment schedules. In the animals which received 20 mg/ kg doses of MTX and FU in combined therapy, no statistically significant differences were found in serum 5-MTHF levels obtained in animals treated with three different schedules. In these groups, the obtained 5 -MTHF levels did not differ from those observed in the group of healthy untreated mice (Table 8) . Table 9 presents the levels of 5-MTHF in the serum of BDFI mice with LI2IO leukemia obtained on the 14t.h day after administration of the drug( s). Identical doses and treatment schedules as in healthy mice were used . Table 10 presents statistical analysis of the obtained results.
It was demonstrated that i I } mice inoculated with L I2IO leukemia the values of 5-MTHF serum levels were significantly lower than those observed in healthy mice. After the lower MTX dose used in the experiments, 20 mg/kg, as well as after FU, the values of 5-MTHF levels were significantly lower than in untreated leukemic mlCe. Number of animals ill group n=lO. X ± SEM-mean± standard error mean. 
Group symbols as in Table 9 . Significance level set at p S O.OS.
After combined therapy involving simultaneous administartion of both drugs of earlier administration of FU, serum 5-MTHF levels in most investigated groups were significantly lower not only t.llarl the values obtained in healthy mice, but also as those obtaiped in untreated mice with L 1210 leukemia. In contrast, 5-MTHF values were higher in most animals after combined treatment in volving earlier administration of MTX, in comparison with the results of MFs and F2M schedules. Howewr, they remained lower than 5-MTHF leve ls obtained in the:: group of healthy animals (Table 10 ) .
Effects of methotrexate and fluorouracil on 5-lvlTHF levels in mouse erythrocytes; according to the schedule of treatment
Effects of the drugs on N 5 -methyltetrahydrofolate levels in mouse erythrocytes were investigated for 20 mg/kg and 40 mg/kg MTX and FU doses in monotherapy.
Effects of combined therapy with MTX and FU according to different schedules were investigated for the combinations of these doses. MTX (40 ) MTX (20 ) FU ( Experimental conditio ns w ere as described in M ate rials and Method. Number of animals in group n =10. X ± SEM-mean± standard e rro r m ean . Table 11 prese nts 5-MTHF levels obtained in the serum of healthy mice on the 14th day after administration of the drug(s ). Table 12 presents statistical analysis of the obtained results.
It was demonstrated that both after administration of MTX alone and as the first drug in combined therapy with FU, 5-MTHF level in erythrocytes was significantly lower than that obtained in the contro l group . In the groups where FU had been administered prior to, or together with MTX, 5-MTHF level in erythrocytes was most frequently significantly higher than the values obtained after combined therapy involving earlier administration of MTX, and did not differ significantly from the values obtained in healthy controls. After FU administered as monotherapy no changes were found in 5-MTHF levels in erythrocytes of healthy mice (Table 12 ) . Table 13 presents the effects on 5-MTHF levels in erythrocytes of mice with L1210 leukemia obtained on the 14th day after administration of the drug(s). Identical doses and treatment schedules as in healthy mice were used . 
Group symbo ls as in T able 11. Significance level set at p :s; 0 ,05 . Table 13 . Experimental conditio ns were as described in Materials and Method. Number of inoculated leukemic cells lOz. Number of animals in gro up n=10 . X ± SEM-mean ± standard error mean. Table 14 . Statistically significant difterences in N "-methyltetrahydrofolate levels in erythrocytes between the groups of RD!', mice with L1210 leukemia after administratio n of MTX, FU and combined therapy according to different schedules
Group symbols as in Table 13 . Significance level set at p S O,05 and *p S O,l. obtained in healthy mice. A significant decrease of 5-MTHF levels in erythrocytes, as compared with healthy controls, was demonstrated after MTX and FU monotherapies as well as after combined therapies according to different schedules. After combined therapy involving earlier administration of MTX (M2F schedule ) there is a tendency towards higher 5-MTHF erythrocyte levels as compared with the values observed in the animals treated with the schedules involving either simultaneous administration of both drugs (~lF s) or earlier administration ofFC ( F2~1 ) I Table 141 .
Discussion
Introduction of combined therapy involving administration of methotrexate prior to fluorouracil to clinical practice was based on the results of in vitro experiments indicating that after the administration of methotrexate the synthesis of purines is blocked .
Phosphorihosilpyrophosphate (PRPP), not utili-7.ed in the synthesis of purines, is available for the synthesis of fluoropyrimidines after fluorouracil administration ( 16, 17 ) . Synergistic action of mcthotn:xate and t1uoro uracil is also explained by the ability of methotrexate polyglutaminates to bind to thyrnidylate synthase, forming a blocking complex: fluorodeoxyuridinomonophosphate plus thyrnidylate synthase plus methotrexate polyglutaminate to replace NS-methylene-tetrahydrofolate polyglutaminate ( 18, 8 ) .
However, no convincing data have been obtained in clinical setting to support the observation that combined therapy is more effective when methotrexate is administered prior to fluorouracil ( 19, 20, 21, 22, 23, 24) . The schedule involving administration of fluorouracil first has also been proposed (25, 26) .
It has also been emphasized that enhanced cytotoxicity of the combined therapy may correlate with the increase of general toxicity ( 11 ) .
The experiments performed in previous own studies have demonstrated that the order of administration of methotrexate and fluorouracil influences the survival time of mice with L1210 leukemia. The longest survival time was obtained when methotrexate was administered prior to fluorouracil. Simultaneous administration of both drugs or earlier administration of fluorouracil yielded worse therapeutic results . The survival time of some animals treated according to these schedules was shorter than of those treated with methotrexate monotherapy (4, 5) .
Methotrexate belongs to the group of drugs with very potent toxic effect on morphotic elements of peripheral blood; the effect of fluorouracil is weaker (27) .
The present study has focused on the assessment of effects of the drugs administered alone or in combined therapy on morphotic peripheral blood elements on folate and cyanocobalamin levels the 14th day after MTX and/ or FU administration. In healthy mice regeneration of morphotic peripheral blood elements occurs at that time ( 13 , 28) .
The performed experiments have demonstrated that inoculation with, and development of L1210 leukemia leads to anemia: a significant decrease of hemoglobin, hematocrit and erythrocyte count takes place in comparison with the values seen in healthy mice (29, 30) . It has been known from the literature that anemias in mice inoculated with neoplasms do not respond to symptomatic treatment with iron, Vitamin B Il , and folic acid ( 31); they require an effective treatment with cytostatic agents. In own investigations, no improvement has been obtained after combined therapies involving simultaneous MTX and FU administration (MFs), or administration of FU prior to MTX (F2M), whereas when methotrexate was administered before fluorouracil (M2F), the values of hematocrit and erythrocytes were significantly higher than those seen in untreated leukemic animals.
The presented study has demonstrated that the development of LI2lO leukemia leads to the decrease of N 5 -methyltetrahydrofolate and cyanocobalamin levels in blood serum and decreases N 5 _ methyltetrahydrofolate levels in erythrocytes.
The decrease of serum and erythrocytes levels of N 5 -methyltetrahydrofolate , as well as of serum level of cyanocobalamin allows the conclusion that anemia due to folic acid deficiency has developed. The time of its development was short because in this type of rodents folic acid is not produced by bacteria present in the intestines (30,32).
The performed determinations of N S -metl1yl-tetrahydrofolate levels in erythrocytes of mice with Ll2IO leukemia demonstrated a decrease of tissue level of this folate. N S -methyltetrahydrofolate was not determined in other tissues; however, it is known that there is a correlation between its levels in erythrocytes and other cells of the organism ( 33 ) . After simultaneous MTX and FU administration (MFs) or FU administered prior to MTX (F2M), N S -methyltetrahydrofolate levels in serum and erythrocytes, as well as cyanocobalamin levels in serum were lower than the values observ;ed in untreated animals with LI2IO leukemia. Administration of the drugs according to the schedule involving MTX administration before FU (M2F) does not result in a decrease of serum cyanocobalamin level and NS-methyltetrahydrofolate deficiency in blood serum and erythrocytes is not more profound than in untreated mice. The values of N 5 -methyltetrahydrofolate and cyanocobalamin concentrations are significantly higher in the animals which received methotrexate prior to fluorouracil than in those treated according to the schedules involving administration of both drugs simultaneously, or earlier administration of fluorouracil.
Interesting results concerning folate and cyanocobalamin levels were obtained in healthy animals which had MTX and FU administered at the same doses and according to the same schedules as the animals with LI2IO leukemia.
In the groups treated with the schedule involving simultaneous administra.tion of both drugs, or administration of fluorouracil prior to methotrexate, N S -methyltetrahydrofolate levels in blood serum were either lower, or within normal limits; N S -methyltetrahydrofolate concentrations in erythrocytes were either normal or slightly dePteridines/ Vol. 8 / No. 3 creased; serum cyanocobalamine level was not lower than normal.
When MTX was administered prior to FU, a decrease of serum cyanocobalamin level and N S - methyltetrahydrofolate erythrocyte level occurred. Serum N S -methyltetrahydrofolate level was either normal or elevated . This elevation may reflect the reduced ability of erythrocytes to utilize this folate (12) .
The ability of erythrocytes to utilize N 5 -methyltetrahydrofolate is affected in healthy mice also after methotrexate administered as monotherapy.
Conclusions
1. The changes in values of N S-methyltetrahydrofolate and cyanocobalamin levels in serum and erythrocytes of mice with LI210 leukemia indicate the development of anemia due to the deficiency of folic acid.
2. The indicators of folic acid deficiency in serum and erythrocytes of leukemic mice are aggravated after combined therapy according to the schedules involving earlier administration of fluorouracil or simultaneous administration of both drugs, whereas they are not aggravated when methotrexate is administered prior to fluorouracil.
3. The results of erythrocyte count and hemoglobin level determination in mice inoculated with Ll210 leukemia indicate that anemia is the least pronounced in the animals treated with combined therapy involving methotrexate administration prior to fluorouracil.
4 . Combined therapy involving methotrexate and fluorouracil administration, most effective in mice with LI210 leukemia, is at the same time the most toxic schedule fo~ the hematopoietic system of healthy animals.
